Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nafarelin + human chorionic gonadotropin
- Development stage
- Unknown
- Lead developer
- Shaare Zedek Medical Center
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intranasal, Subcutaneous
01
Overview
This refers to a combination therapy protocol developed and studied at Shaare Zedek Medical Center for luteal phase support in women undergoing natural cycle frozen embryo transfer (FET) for infertility. The protocol typically involves the administration of a Gonadotropin-Releasing Hormone (GnRH) agonist, such as nafarelin (Synarel) or triptorelin (Decapeptyl), in conjunction with human chorionic gonadotropin (hCG). The mechanism of action involves the GnRH agonist stimulating the pituitary gland to secrete luteinizing hormone (LH) and potentially exerting direct beneficial effects on the endometrium and the developing embryo via GnRH receptors. The addition of hCG further supports the corpus luteum's function. This combination is compared against standard vaginal progesterone to improve pregnancy rates in natural cycle FET.
- Brand names
- OvitrelleDecapeptyl
- Other names
- triptorelin + human chorionic gonadotropinGnRH agonist + hCGGnRH agonist + hCG luteal support
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on nafarelin + human chorionic gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nafarelin + human chorionic gonadotropin.